title: Transdermal Scopolamine and Acute Postoperative Urinary Retention in Pelvic Reconstructive Surgery.
abstract: To evaluate the relationship between perioperative use of transdermal scopolamine and the rate of urinary retention after stress urinary incontinence and pelvic organ prolapse procedures in women.
  
  
  
  This is a retrospective, cohort study; the primary outcome is the rate of acute postoperative urinary retention. Study candidates were adult female patients who underwent pelvic reconstructive surgery at a tertiary care center. Subjects were excluded if preoperative postvoid residual urine volume was greater than 150 mL, preoperative urodynamic testing was not performed, or if a postoperative trial of void was not performed. Subjects were grouped based on preoperative use of transdermal scopolamine. Patients were selected consecutively until 138 subjects per group was reached. Differences in rates of acute postoperative urinary retention were evaluated using a chi-square test. Group demographics were evaluated using t tests and χ tests.
  
  
  
  Two hundred seventy-six subjects were included in the analysis, 138 received a transdermal scopolamine patch in the perioperative period and 138 did not. The overall rate of acute postoperative urinary retention was 25.3%. There was no significant difference in the rate of acute postoperative urinary retention between the study groups (scopolamine, 26.8%; no scopolamine, 23.9%; P = 0.580). Demographics of the 2 groups were compared; patients who received scopolamine patch were younger (P = 0.001), received a greater amount of intravenous fluids (P = 0.007), and underwent a greater percentage of incontinence procedures (P = 0.048). Otherwise, there were no differences between the groups.
  
  
  
  Transdermal scopolamine is not a risk factor for acute postoperative urinary retention after pelvic reconstructive procedures.
authors.affiliation: From the *Division of Urogynecology, and †Research Administration, Hartford Hospital, Hartford, CT.
authors.forename: Katie
authors.initials: K
authors.lastname: Propst
authors.forename: David M
authors.initials: DM
authors.lastname: OʼSullivan
authors.forename: Paul K
authors.initials: PK
authors.lastname: Tulikangas
mesh_terms: D000279:Administration, Cutaneous; D000368:Aged; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D005260:Female; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D056887:Pelvic Organ Prolapse / Q000601:surgery; D011183:Postoperative Complications / Q000209:etiology*; D011184:Postoperative Period; D019651:Plastic Surgery Procedures / Q000009:adverse effects*; D012189:Retrospective Studies; D012307:Risk Factors; D012601:Scopolamine / Q000008:administration & dosage / Q000009:adverse effects*; D014550:Urinary Incontinence, Stress / Q000601:surgery; D016055:Urinary Retention / Q000209:etiology*
chemical_list: D018727:Muscarinic Antagonists; D012601:Scopolamine